Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for ...
Scientists have pinpointed the binding site for low-dose ketamine on NMDA receptors, explaining its fast-acting effects on ...
Researchers at Tel Aviv University have made a fundamental discovery: the NMDA receptor (NMDAR)—long studied primarily for ...
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...
Earlier this year, a phase 2a, 167-patient Alzheimer's-related depression trial recruited ... denier but a certified fan of ...
Computer-assisted cognitive-behavior therapy (CCBT) and mobile mental health applications warrant continued development and ...
FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback